Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;11:3015. doi: 10.1038/s41467-020-16827-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, b, Immunoblot analysis of Akt activating phosphorylation (Ser473) in T4121 GSCs (a) and T387 GSCs (b) treated with 5 μg/ml Integrin blocking antibody (Anti-Integrin ab) or relative isotype IgG control in combination with WISP1 overexpression or vector control for 48 h. α3, Integrin α3; α6, Integrin α6; α7, Integrin α7. c, d, Cell viability (c) or tumorsphere formation (d) assay of T4121 GSCs treated with 5 μg/ml Integrin α6 blocking antibody (ab) or isotype IgG in combination with WISP1 overexpression or vector control. n = 6 biological independent samples. Data are shown as means ± s.d. ****p <0.0001, two way ANOVA analysis followed by Tukey’s multiple test (c). ****p <0.0001, two-tailed unpaired t-test (d). e, f, Cell viability (e) or tumorsphere formation (f) assay of T4121 GSCs treated with Integrin β1 blocking antibody (5 μg/ml) or isotype IgG in combination with WISP1 overexpression or vector control. n = 5 (e) or 6 (f) biological independent samples. Data are represented as mean ± s.d. ****p <0.0001, two way ANOVA analysis followed by Tukey’s multiple test (e). ****p <0.0001, two-tailed unpaired t-test (f). g, h, Cell viability (g) or tumorsphere formation (h) assay of T4121 GSCs treated with Integrin blocking antibody (5 μg/ml) or isotype IgG for 6 days. n = 5 biological independent samples. Data are represented as mean ± s.d. ***p = 0.001, ****p <0.0001, two-tailed unpaired t-test. α6, Integrin α6; β1, Integrin β1; β4, Integrin β4. i Immunoblot analysis of Akt phosphorylation (Ser473) and Integrin α6 expression in T4121 GSCs transduced with shIntegrin α6 or shNT control. j, k, Cell viability (j) or tumorsphere formation (k) assay of T4121 GSCs transduced with shIntegrin α6 or shNT. n = 5 biological independent samples. Data are shown as means ± s.d. ****p <0.0001, two way ANOVA analysis followed by Tukey’s multiple test (j). ****p <0.0001, two-tailed unpaired t-test (k). Source data are provided as a Source data file.